Swissmedic 就平行进口人用药品指南发布补充说明,明确一级包装不得加贴附加标签
Additional information on the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (par...
Swissmedic 发布补充说明,明确平行进口人用药品不得在既有境外一级包装上加贴附加标签。该说明针对 2026 年 10 月 1 日更新的《按 TPA 第 14 条第 2、3 款进口人用药品(平行进口)》指南第 5.5.1 节,已获批且曾获准加贴附加标签的产品须在通告发布后一年内提交删除标签的变更申请。已放行批次不受该规定影响,新批次可按现行获批包装设计继续放行至变更程序完成。
材料划定平行进口药品一级包装不得加贴附加标签的要求边界,并给出一年的变更申请过渡期,便于核对已获批标签与批次处理时点。
Additional information on the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Additional labels on primary packaging are not permitted for parallel imported human medicinal products. Medicinal products that have already been authorised have a transitional period of one year to apply for the required changes
02.11.2026
As part of the update of the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)” of 1 October 2026, it was explicitly clarified in the requirements for primary packaging in section 5.5.1 that affixing of additional labels to existing foreign primary packaging is not accepted. This applies in particular to labels providing translations of information into the official Swiss languages, irrespective of the format and material of the primary packaging or the position of the area to be covered by the affixed label.
The following transitional rule applies to parallel imported medicinal products that have already been authorised and for which additional labels on the primary packaging were approved:
- An application for variation to remove the additional labels must be submitted within a year of publication of this communication.
- Batches that have already been released are not affected by this rule and can continue to be placed on the market and sold.
- New batches can continue to be released according to the currently approved design of the primary packaging until the variation procedure is completed.
Swissmedic recommends that affected marketing authorisation holders plan the necessary changes and submission of the relevant variations in good time.
来源:Swissmedic 药品质量与 GMP 更新 · swissmedic.ch